Carcinoma of the vulva accounts for 4% of all female genital tract malignancies. 1 The incidence in the UK is two per 100,000 female population. 2 Vulval cancer is rare in young women with rates of more than one per 100,000 among women aged 25-44 years in the UK. 2 In the US, 15% of vulval cancers are reported to occur in women <50 years of age. 3, 4 Prior studies have reported an incidence of 3.3% in women <35 years old, 5 2.3% in women <40 years old and 6.1%
Vulval Carcinoma in Pregnancy
Regarding the 21 cases of vulval carcinoma presenting during pregnancy or the post-natal period (up to three months post delivery), mean age at presentation was 29 years (range 17-39 years), the majority were multiparous (n=17; 80%), none were HIV-positive and one was immunocompromised (pregnancy-related bone marrow hypoplasia). 36 The majority of women presented in the second (n=9, 43%) or third trimester (n=9, 43%), with only three women (14%) presenting in the post-natal period. 9, 37, 38 The presence of a vulval mass (n=11, 52%) was the most common presenting complaint (n=5, 23%; vulval pruritus n=1, 5%; vulval pain 5%; vulval wart 5% incidental finding at delivery). All but one woman required some form of surgical management.
One woman diagnosed at 19 weeks' gestation defaulted from surgery. 25 In total, 11 of 18 women (61%) had a surgical procedure performed in the antenatal period: six of those (55%) were performed in the second trimester of pregnancy and five (45%) in the third trimester. Apart from the three women diagnosed in the post-natal period, one presenting at Following primary vulvar surgery in the antenatal period, two women had further post-natal lymphadenectomy surgery. 27, 43 The surgical complication rate for the 11 women operated on in the antenatal period was 36%, with two women having significant haemorrhage 37, 44 and two incurring groin seromas. 45, 46 The surgical complication rate for those operated on in the post-natal period was also 36% (one wound infection, 37 one wound breakdown, 38 one septicaemia 39 and one groin haematoma). 9 The majority of tumours were early stage (47% weeks' gestation; 6 and one pre-term labour and delivery at 29 weeks' gestation. 40 A further woman undergoing a radical vulvectomy and lymphadenectomy at 23 weeks also developed a recurrence of her carcinoma at 34 weeks' gestation. 47 Mode of delivery was documented in 20 women: eleven (55%) delivered vaginally (10 spontaneously, one by forceps); of the remainder, three (33%) had a Caesarean section for obstetrical reasons and six (66%) had a Caesarean section due to either the presence of vulval scarring (n=2) or the presence or diagnosis of vulval cancer (n=4). One woman had a bilateral episiotomy performed 37 and one sustained a fourth-degree perineal tear. 43 Squamous Cell Vulval Carcinoma and Pregnancy -A Review 
A+W = alive and well; BFL = bilateral femoral lymphadenectomy; BIFL= bilateral inguinofemoral lymphadenectomy; BIL = bilateral inguinal lymphadenectomy; BIPL = bilateral inguino-pelvic lymphadenectomy; BL = bilateral lymphadenectomy; CS = Caesarean section; FIGO = International Federation of Gynecology and Obstetrics; IUD = intrauterine death; NR = not recorded; NVD = normal vaginal delivery; PL = pelvic lymphadenectomy; RV = radical vulvectomy; VR = vulval reconstruction; WLE = wide local excision.
Six women underwent post-natal radiotherapy. Three further deliveries were recorded with two having a normal vaginal delivery 37 and one Caesarean section 28 months after treatment. 6 Maternal outcomes were recorded in 81%, although duration of follow-up was highly variable. Five women were recorded as dead from disease (range nine weeks to 48 months) and 12 were recorded as alive and well anywhere from four to 96 months (see Table 1 ).
Pregnancy Following Vulval Cancer
Regarding the 13 cases of pregnancy following vulval cancer, mean age at pregnancy was 31 years (range 19-39 years), the majority were nulliparous (n=9; 69%) and none were immunocompromised. All women had undergone prior vulval surgery with lymphadenectomy, and none had prior radiotherapy. All women were reported as alive and well (see Table 2 ).
Discussion
Malignancy is uncommon in pregnancy and maternal vulval malignancy These recommendations hold well in the present day.
This literature review spans more than 65 years, hence we must take into account significant changes in the management of vulval cancer and changes in obstetrical and neonatal care. The practice of pelvic lymphadenectomy is now obsolete 60 and, although surgery to the primary tumour should be radical enough to remove the tumour with adequate margins, triple incision techniques are now employed.
Compared with more recent modifications in surgical practice, it is likely that some of the reported cases in the literature underwent more radical surgery than would be performed in today's environment.
As wide local excision of the primary tumour in early-stage disease may suffice, and lymphadenectomy is less extensive, consideration should be given in pregnancy to the use of regional as compared with general anaesthesia. Surgical morbidity is reported as being proportional to genital vascularity, which increases throughout pregnancy, 27, 38 with increased vascularity increasing the risk of surgical haemorrhage. 39 Therefore, the risk for potential haemorrhage and increased risk of thromboembolic complications should be accounted for.
Inguinofemoral lymphadenectomy may be associated with considerable post-operative morbidity, hence the avoidance of more radical procedures where deemed unnecessary (i.e. in negative nodal disease).
Currently, no non-invasive procedure available can reliably detect nodal metastases. Systematic review suggests that computerised tomography (CT), ultrasound, magnetic resonance imaging (MRI), positron emission tomography (PET) and fine-needle biopsy show inconsistent results and are not accurate enough for the routine assessment of groin node status. 61 Sentinel node identification is currently the most promising diagnostic tool for the assessment of lymph node status in vulval carcinoma, [62] [63] [64] [65] [66] but its safety is still to be proven. 58 Clearly in pregnancy
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contrast dyes and radiolabels should be used with caution, yet it has been reported that sentinel lymph node biopsy can be performed in pregnancy with negligible 67, 68 or very low risk 69 to the foetus.
Adjuvant or neoadjuvant radiotherapy and chemotherapy may be utilised in the treatment of vulval carcinoma, with cisplatin and 5-fluorouracil (5-FU) being the more commonly investigated chemotherapeutic agents. [70] [71] [72] [73] [74] [75] When considering the use of either radiotherapy or chemotherapy in the pregnant patient, the risk of exposure to the foetus and neonate and the potential risks of delaying therapy to the mother in view of the pregnancy are highly significant matters. Radiotherapy should be avoided during pregnancy whenever possible 76 and delayed until after delivery. 77 All chemotherapy agents are potentially teratogenic. 78 Although cisplatin is the most widely researched and most commonly used chemotherapy agent during human pregnancy, 79 5-FU has been less widely studied. Studies in rats suggest that the neuroembyopathic effect of 5-FU is severe when given in the early and late phases of pregnancy, [80] [81] [82] so it is advisable that the drug is avoided during pregnancy. Therapeutic abortion is a consideration for women presenting with advanced-stage or unresectable disease in early pregnancy. consideration must be taken as to the possible risk of laceration and haemorrhage associated with vaginal birth. 7 Also if the lesion is close to the perineum then performance of episiotomy may be difficult due to potential encroachment onto the tumour. 44 When vulval surgery is performed later in the second and third trimesters, vaginal delivery runs the risk of wound dehiscence or wound complications; in these circumstances, delivery by Caesarean section may be appropriate. 39, 44 Vulva scarring or prior vulval plastic reconstructive surgery may influence the decision to perform a Caesarean section. 29, 45, 50 Delivery by Caesarean section may also be preferred by the woman. 45, 50 In the successfully treated vulval cancer patient there seems to be no contraindication to future pregnancy. 36, 39, 40, 50 Both vaginal delivery 6, 31 and Caesarean section 6, 49 have been reported. We found a 62% Caesarean section rate in those having had prior treatment for vulval cancer, where four (50%) were performed in view of significant vulval scarring.
It is possible that maternal vulval carcinoma or prior treated vulval cancer may increase the likelihood of delivery by Caesarean section.
Therefore, it seems pertinent that women are advised of this likely risk.
The reported mortality rate for vulval carcinoma is lower in women who are between 25 and 44 years of age than in those >45 years of age. 83 Five-year relative survival rates for vulval cancer have been shown to decrease with increasing age at diagnosis. 84 It appears that pregnancy exerts no deleterious effects on the course of disease or prognosis. 27, 37, 40, 44 It is also likely that subsequent pregnancy following treatment for vulval cancer has no adverse effect and is not shown to increase the risk of recurrence. 6, 29, 31 We are unable to draw any conclusions regarding overall survival due to reporting variations in the duration of follow-up of these patients. For women diagnosed with vulval cancer in pregnancy, follow-up should run as standard vulval cancer management within a cancer centre. Examination of the groin and vulva should be performed during pregnancy as prior recurrence of disease during pregnancy has been reported.
47

Conclusion
The diagnosis of vulval carcinoma during pregnancy is a rare event, as is pregnancy following treatment for vulval cancer. There is a suggestion that the incidence of vulval carcinoma is increasing in the younger age group. It is therefore likely that the incidence of vulval cancer in pregnancy will also increase. There is no single institution that can report a large series of maternal vulval cancer unless over an extended period of time, hence not allowing for significant changes in the management of vulval carcinoma and significant changes in obstetrical and neonatal care. Furthermore, multi-institutional co-operative groups could not study this issue. Only an extensive review could compile this information. We recommend that future case reporting contains detailed information on clinicopathological variables and treatment regimens. As longer-term maternal and neonatal outcomes are more difficult to substantiate in case reporting, the authors feel that data centralisation would be beneficial in identifying optimal management strategies in not only these rare tumours, but also in other malignant tumours diagnosed and treated during pregnancy. n Squamous Cell Vulval Carcinoma and Pregnancy -A Review His work on Ion Transport Across the Human Placenta was awarded a DPhil in 1992.
